Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Joel M, Basken"'
Autor:
Andrew J, Kavran, Scott A, Stuart, Kristyn R, Hayashi, Joel M, Basken, Barbara J, Brandhuber, Natalie G, Ahn
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 119(12)
Patients with melanoma receiving drugs targeting BRAFV600E and mitogen-activated protein (MAP) kinase kinases 1 and 2 (MEK1/2) invariably develop resistance and face continued progression. Based on preclinical studies, intermittent treatment involvin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::206e1ec6caeb4f6bfa7ef6795d906ce0
https://pubmed.ncbi.nlm.nih.gov/35290123
https://pubmed.ncbi.nlm.nih.gov/35290123
Autor:
Andrew J. Kavran, Scott A. Stuart, Kristyn R. Hayashi, Joel M. Basken, Barbara J. Brandhuber, Natalie G. Ahn
Publikováno v:
Proceedings of the National Academy of Sciences. 119
Significance Preclinical studies of metastatic melanoma treated with targeted therapeutics have suggested that alternating periods of treatment and withdrawal might delay the onset of resistance. This has been attributed to drug addiction, where cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5d6da36ee88f4d1d62cb102063d27b4
https://doi.org/10.1073/pnas.2113535119
https://doi.org/10.1073/pnas.2113535119